it's growing significantly faster than pharma. guess what?cheaper based on forward earnings. >> all right, dr. j, give me a pick. >> merck. >> all right. later on cnbc, be sure to check out the exclusive interview with james gorman, "street signs" today, as you see, 2:35 eastern time. >>> the pops and drops, the biggest movers. joe, urban outfitters, a big drop. >> it is. unfortunately, what you're seeing here is the comps coming in midsingle digits. i'm going to wait a couple of days. i'm going to buy this name. i like the strength we're seeing in an throe polg -- anthropology. >> fusion io. >> yeah, it had some chatter, some upgrade, as well as people at conferences talking about fusion. it had a very significant top, though, about 25%. i think it has a little more room to pull back before it goes higher. >> murph? pbh. >> it actually came out with decent earnings. it was the guidance that got people spooked. it continues to sell off. right now, we're sitting down about 7%. the stock ran up into it, and they just -- the guidance will not su

the onions of americans are developing sleep disorders and a new dependency on big pharma. a breakdown on how these sleep friendly drugs are ruling the nation. it is tuesday, september 10 at 5:00 p.m. in washington dc. we begin with syria where military action might be shifting. accepting a russian proposal to lace the chemical weapons under the supervision of the u.n.. the russian counterpart was not enthusiastic about a binding resolution that would provide a framework. it is difficult to make any country, syria or any other, to unilaterally disarm if there is monetary -- military action under consideration. international chemical weapons convention. syria was one not signing the treaty. they said we are ready to fulfill our obligations in compliance with this treaty. we will open our storage sites and cease production. we are ready to open these facilities to russia and the united nations. majority leader harry reid announced it would -- he would postpone a vote to authorize military action. the house of representatives continue to debate the issue. holding a hearing ear

then there's excelleron pharma.remiere, a provider of supply chain services to doctors and hospitals all over the country priced at $27 last night. these are getting lost in the shuffle, these are amazing. these are amazing, and those are -- those are just the health care deals. tech ipo's have been incredibly hot too. rocket fuel, a rapidly growing big data play came in at 29 last week, we're 93% higher than the first day of trading. then there are a couple tech deals i told you to get in on two weeks ago. benefit focus. benefit focus is a cloud base. how much the rage is cloud, cloud based provider. this one was viewed as the next red-hot cloud play. when it came public last week, the stock jumped 102%. an instant double. fire eye is the cyber security play. you know how important that is, even though it's ipo prices 54% higher than the initially proposed range. the stocks still were up 80% on its first day of trading. now, it should go without saying, but i'll say it anyway, if you got a piece of these smoking de

patients life for as long as the physician says they need it the drug is given it's a big boon the pharma company has this kind of project. x. is a drug like this this drug is a marvelous drug. fifteen thousand patients take three hundred thousand take the mts. doctor but the health care system cannot rely on novartis as project. they have entered this group certain hospitals and. so there it is need from that point of charity efforts which the will to shoot the social responsibility on to note if the poor and weak use of the. to the deceased because of the. two and individually for that drug. mission in three couldn't take should be free in-store charge is free. range means free risk free stew type free. download free broadcast quality video for your media projects a free media and on to our teeth dot com. over to go digital the price is the only industry specifically mentioned in the constitution and. that's because a free and open press is critical to our democracy trek albus. role. in fact the single biggest threat facing our nation today is the corporate takeover of our government an

patients life for as long as the physician says they need it the drug is given it's a big boon the pharma company has this kind of project. x. is a drug like this this drug is a marvelous drug. fifteen thousand patients take glivec three hundred thousand take them out. doctor. the health care system cannot rely on this project. they have entered this group certain hospitals. would be complete so they needed need from that point of charity to the efforts which the two should. social responsibility to note if the poor and weak use of the. sun to the deceased because of the ability to and individually for that drug. sympathize with the soon to uprising but we do not train and we do not smuggle weapons or send a snake we do not do any of these things. choose your language killing we kill without any federal official some other. treatments that is the consensus you can. choose the opinions that immigrate to. choose the stories that in high life choose the access to your office. led. her. economic ups and downs in the final months the longer the deal and the rest of the. case it will be if we c

a lot of pharma deals going on so see if this gets bought out in the next few days. next one is newskin, beauty products. i am buying into this. >> they are growing rapidly in asia driving a lot of revenue from that part of the world and there's a lot of growth left, stock doing extremely well, it is down a little bit today and i see 10% over the next 20 days and again if your luck is going to run out, no et efiks either. i was watching you. cheryl: you got in a lot of trouble on that picket. >> yes i did. i took some heat for that's all i came on strong resist time. cheryl: your last stock tech, you will know this one, you like linkedin. >> you got to like oliver said look where the strength is in the market. relative strength in the biotechs rendell. and we talk about alan mulally, a great working guy, leading to all-time highs and the stock will do very well. cheryl: i thought you were going to the was going to take over microsoft in your pick for ceo. >> i will connect with him on linkedin. cheryl: one interesting thing it is up 112% over the last year. i got to

patients life for as long as the physician says they need it the drug is given it's a big boon the pharma company has this kind of project. x. is a drug is this drug is a drug. fifteen thousand patients take three hundred thousand take beam out. doctor but the health care system cannot rely on novartis as project. the head. of this group certain hospitals. and so they do need to go from that point of view. to the efforts which the two should. social responsibility to note if the poor and to make use of to. succumb to the deceased because of the ability to and. that drug. i think. we're going to go digital the price is the only industry specifically mentioned in the constitution and. that's because a free and open process is critical to our democracy correct albus. in fact the single biggest threat facing our nation today is the corporate takeover of our government and across several we've been hijacked why a handful of transnational corporations will profit by destroying what our founding fathers once it's all just my job market and on this show we reveal the big picture of what's actuall

cutting deals he wanted deals with pharma. if you're on the left, you should be fighting for public option. this is the worst of chronny capitalism. >> no, we fought and lost, but it would be in some wayings israeli occupation of palestinians. do they have universal health care there? it's a matter of trying to be inclusive. the problem is you have issues of race and class, those in the hoods, those on the reservations, in the barrios, they are not even part of the conversation. in the same way it's hard for palestinians to be hard of the conversation with our jewish brothers in the state of israel. >> medicaid is what you said. single pair public option. do you want to spread medicaid -- >> we're talking about medicare to medicaid. >> it's not single payer public option. >> i want to know what you want, though, sir. >> i'm for conservative reform. it has to be reformed. >> let me lay this out and you tell me where i'm wrong. right now, we have the worst of all possible worlds. if somebody gets hit by a bus we're not going to

i'm talking about pharma si cyclics. pcyp, stuck their necks out and recommended it.hink they're right. now i can give these guys a hard time for being late to the party, including myself. because it's rallied 129% since the beginning of the year. it's up 1,532% over the last three years. but i prefer to be constructive and to be fair, it's not like i nailed it either. the truth is, with a stock like pharmacyclics, we don't care about where it's come from, right? we only care about where it's going to. and basically what's happening at this company, i believe it has more room to run, which is why i'm highlighting it for speculation friday. see, if appears as though pharmacyclics has developed an anti-cancer therapy with a drug that could put celgene's incredible flagship blood cancer franchise revlimid -- i don't want to say to shame because it's too good but could really overshadow it down the road. the pharma cyclic drug is called ibrutin ibrutinib. i'm going to mispronounce it several times. the company submitted it to the fda over the summer, and the fda will like

acceleron pharma-- will price shares between $13 and $15 dollars. the ticker symbol will be x-l- r-n. the company develops protein- based drugs to treat rare blood disorders. bind therapeutics will sell shares any where from $14 dollars to $16. the ticker will be bind. its business is focused on devoloping drugs to treat lung and prostate cancer. as ford's car and truck sales motor along.. standard and poors is upgrading its credit rating.. s&p is lifting ford to investment-grade. a big improvement from the days of the recession. it's a sign the car company has a low risk of defaulting on its debt. ford reportedly holds $30 billion in cash and lines of credit. and ford's ceo is clearing up rumors of a possible departure from the company. alan mulally tells cnbc hes "absolutely focused on ford." it follows whispers that the automaker's board is open to letting him step down to explore other options. ford says mulally plans to serve as the president and ceo through at least 20-14. the uaw is attempting to make inroads at a vw factory in chattanooga, t

trial of gadhafi son in may this year but that request was rejected now earlier my colleague andrew pharma swear to a libyan lawmaker who serve the country has every right to try gadhafi son without foreign interference take a listen. so if we get there because he's a libyan all the crimes on the charges against him that they've been proud of committed in libya and i. believe that he should be tried in libya none of the none of the crimes that he's been charged with are committed outside libya so there's no reason whatsoever to to to try him outside libya and the demand of all libyans why do you think this being such a battle then as to where to try him where the president the president is not we as a libyan who have had their pollution in two thousand and eleven we don't have a brother we knew we knew from day one we wanted to try all of them including see if we get there been in libya you can catch all the stories we're covering and much more on our website including itself a shot for america's ever expanding drone program but how is that hand just start offering to reason unmanned aeria

coming to you live from moscow with me andrey pharma now addressing the u.n. general assembly iran's president hassan rouhani says he's ready for dialogue on the country's nuclear program he's called for a consistent voice from washington on the issue while obama also signaled his willingness to talk on the sidelines of the gathering in new york russia and the u.s. also continued their work on a consensus over syria artie's nice and now he has this report. at his debut speech at the u.n. iranian president hassan rouhani stressed iran is not a threat but made to be won by other countries to promote interests in the region he said no military solution is acceptable in the region and the syrian crisis is a result of external influence to change regional order now rouhani talked about how people in the world are tired of wars and violence and how moderation is needed he added that iran is ready to cooperate he once again said iran is not seeking nuclear weapons and is ready to help quell concern over its peaceful nuclear program but only at sea you know on iran's

dahlia will welcome global leaders and finance heavyweights today for what has come to be known as the pharma doubles the three day annual meeting of the new champions of the world economic forum as it's officially titers will feature all the double settlements the global leaders the business heavyweights the save the world policies just minuses. but with the forever valving global economy and china's increasing economic power in contrast years growth this asia event really highlights the economic shift east despite a recent slow downturn as economy is still posting enviable growth figures just this week china's industrial production rose by more than expected in august along with actually output and retail sales the latest signs that the world's second largest economy is still robust so with china demonstrating a resilient economy this begs the question why have a world economic forum in europe sure where greed is astounded as the flowers on the mountain tops added to this following on from the g. twenty summit is pieces about the foundations of the one hundred billion dollar bric developmen

with me andrey pharma. now syria's chemical weapons must be removed or destroyed by the middle of next year under a deal reached by the us and russia there are six key points in the ground breaking agreement so let's take a look at what they are firstly the exact quantity of syria's chemical weapons will be determined and put under international control but first syria will have to submit a full list of its stockpiles within a week and after that these arms can be destroyed under the chemical weapons convention international inspectors will get immediate access to weapons storage facilities to begin the destruction process and if syria doesn't comply it could lead to a chapter seven u.n. security council resolution which does allow the use of force and he said now reports this deal doesn't necessarily mean though that the threat of a u.s. strike is no longer looming over syria. signed sealed and if delivered it could see syria hand over its chemical weapons stockpiles russia and the us agreed on a six point

alone millions of americans are developing new sleep disorders and with them a new dependency on big pharma a full breakdown on how these sleep friendly drugs are ruling the nation later in the show. it's tuesday september tenth four pm in washington d.c. i'm the mere idea of it and you're watching our t.v. we begin today with syria where the conversation on potential military action may be shifting a diplomatic solution is now on the table with syria formally accepting a russian proposal to place their chemical weapons under the supervision of the international community however today france's foreign minister told reporters his russian counterpart was not enthusiastic about a binding un resolution on syria that would provide a framework to control the country's chemical weapons stockpile russian president vladimir putin said this of the proposal certainly this is all reasonable it will function and will work out only if the u.s. and those who support it on this issue pledged to renounce the use of force but it is difficult to make any country. syria or any other country in the world to un

alone millions of americans are developing new sleep disorders and with them a new dependency on big pharma a full breakdown on how these sleep friendly drugs are ruling the nation later in the show. it's tuesday september tenth eight pm in washington d.c. i'm lynn neary david and you're watching our t.v. we begin tonight with syria where the conversation on potential military action may be shifting a diplomatic solution is now on the table with syria out formally accepting a russian proposal to place. provision of the international community however earlier today france's foreign minister told reporters his russian counterpart was not enthusiastic about the binding un resolution on syria that would provide a framework to control the country's chemical weapons stockpile russian president vladimir putin said this of the proposal certainly this is all reasonable it will function and will work out only if the u.s. and those who support it on this issue pledge to renounce the use of force because it is difficult to make any country syria or any other country in the world to unilaterally disarm

alone millions of americans are developing new sleep disorders and with them a new dependency on big pharma a full breakdown on how these sleep friendly drugs are ruling the nation later in the show.

alone millions of americans are developing new sleep disorders and with them a new dependency on big pharma a full breakdown on how these sleep friendly drugs are ruling the nation later in the show.

pharma. >> point being, regardless of -- ir regardless -- i think you're better off in biotech. >> grassorises on the gates above? >> i don't like the chart here but if you are going to play it long use a long term fib trace of 3720 as your out. >> last one for mike khouw, in the khouw's nest should investors follow icahn into nuance communications? >> generally speaking following one person into a stock isn't the best way to run. in the case of carl icahn i might be for it. this stock has been beaten up significantly. it's probably trading a little over 14 times full year eps. i don't think there is too much risk to the downside if you start to dip your toe into the water to figure out what he's all about. he's probably the best contrarian investor in the world. if you are going to take your cues from anybody he's not a bad one to pick. >> coming up next your first move tomorrow. [ female announcer ] it's time for the annual shareholders meeting. ♪ ♪ there'll be the usual presentations on research. and development. some new members of the team will be introduced. the chairman emeritus wi

that's not even the companies with big pharma players that could bring in billions of dollars in milestoneayments that could be one or two a year. sgen has given us an 88% gain since we spoke to the company's ceo just last december. i think it has more room to run so let's check in with dr. clay segal. he's the chairman, president and ceo of seattle genetics, and find out more about where his company is headed. welcome back to "mad money." >> nice to be here, jim. >> have a seat. thank you so much. i've been thinking about this drug and all of the different applications. it seems like it is a pipeline in itself. >> yeah. as you said, we have over clinical trials along with etceteris, four phase threes, and different disease settings and frontline therapy. so when you're first diagnosed. our approval is hodgkins lymphoma and in the relapsed settings and we're redefining what patients get in the front line. >> in the conference call you did mention some of the doctors are trying to use it off label. is this because it's saving more lives than what they're currently using? >> it's not an incr

now, tech similar to pharma has been dealing with dwindling pipelines and slowing growth.h giants like microsoft and apple have been putting more focus on increasing shareholder value. in fact in the second quarter according to iq, tech maintained buyback accounting for 34.5% of all expenditures. >> our own kate kelly spoke exclusively with head of the firm that's the newest microsoft board member. kate, what did you find out? >> well, maria, it's interesting. speaking of this surprise high dividend today, some people think his firm value act capital may have had some involvement in the decision to boost it 22%. while they haven't said a lot about their involvement, they have been around at a time of significant changes at the company. essentially valueact, a $12 billion long only investor, disclosed a stake earlier this year of roughly $2 billion in microsoft. not long after that, steve ballmer announced plans to resign and valueact, as mentioned, was given a seat on the company's board starting as early as the first quarter of next year. at an investment conference today

i know there's a lot of people being financed by big pharma. i am not. just me telling you what i have tried, what worked, what didn't work, what i do myself, where i got results, and to bring controversial topics to air and have you make your own decisions about whether or not you want to follow that. >> because there are some controversial topics out there. >> in health everything seems to be controversial these days. >> why do you think that is? >> there's the conservatives who -- they're m.d.s and pharmaceutical companies and on the other side is the alternative and homeopa yopathid the people in between who do a mixture. on the far end sides, it's like the lefts and the rights, everybody is arguing over what's the right thing. >> what will we see on today's program? >> we're talking about a uv light that cleans your pool. you can do it without chlorine or with a little bit of chlorine, your choice, but it's a chemical-free pool. also the kids are going back to school so we're talking about healthy snacks, but i made it one step further and i talked

breaking the law drug dealers who push pot can't write off their lawyers fees but drug dealers a big pharma even when they lie and break the law in ways that kill people something potts never done can write off those lawyers. fees all because they're incorporated all these breaks come in exchange for the company receiving those benefits giving society something back in return besides a useful service like selling meals or a good product like a well made car the single most important thing a business owner can give back to society is well paying jobs with benefits a job that pays a living wage isn't just good for the workers who get to take home a livable paycheck it's good for other business owners and the economy as a whole businesses need people with reasonable incomes to buy their goods when workers are paid so little that they can barely afford to eat they can't spend additional money and as a result the entire economy suffers this is econ one hundred one that implicit contract between society and the business owner used to be common knowledge in this country until the reagan revolution

shares of vie ro pharma are surging on a story from bloomberg that rare drug disease maker that one is said to have hired goldman sacks to explore a possible sale. this report says european drugmakers are said to be interested. this could be the latest in a string of acquisitions by bigger drug companies. shore up their product pipelines. viropharma trading at its highest level since 2001. >>> a former treasury secretary, bank ceo and hedge fund manager walk into a bar. miley cyrus -- just kidding. no joke. we had the trio minus miley on squawk box to reflect on the financial crisis and also to talk about today's big issues. mary thompson on what they had to say. >> it was interesting tv, tyler. one helped save the financial system during the crisis the second resents the fact that his bank had to take t.a.r.p. money and the third made money. hank paulson, former wells fargo ceo dix kovacevich and mark of avenue capital reflecting on the crisis and ricks out there today. paulson's concerns include the adjustment to a higher rate environment and need to reform immigration, tax code and

i truly believe that whether it's big alcohol, big tobacco or big pharma, a company like one of thoseg to look very, very closely at medical cannabis. it's about a $2 billion market in 2012, growing to just under $9 billion in 2016. so you're seeing hockey-stick growth. and i think companies like dixie are well positioned to be acquired as the industry develops. >> kroft: it's a risky proposition. the industry requires a big capital investment and the medical marijuana marketplace is already saturated. but matt cook, who wrote the rule book for all this and is now a consultant to the medical marijuana industry, says it's helped pull denver out of the recession, occupying once vacant retail and industrial space, providing thousands of jobs and new revenue for the state of colorado. what's the economic impact been? >> cook: it's huge. there's over a million square feet of leased space in the denver area. look at all the electrical contractors, the hvac contractors, a number of ancillary businesses. it's huge. tax revenues exceeded... i believe the last number i heard was in excess of $2

which brings me to biomarin pharma, the developer of orphan drugs for ultra rare genetic disorders andogize in advance, i'm going to pronounce a lot of stuff that will be difficult for me. it's very difficult. earlier i explained why biomarin's chart is looking red hot. and that's according to bob lang at realmoney.com. now i've got to talk about the business. here we go. let's give it a shot. the company specializes in enzyme replacement therapies for rare and incurable genetic disorders that otherwise would go untreated. four drugs on the marketplace. two of them treat a condition called mps, causes horrific damage at the cellular level if left untreated. another one helps manage pku, which can cause severe development problems and neurological issues, and biomarin's fourth drug treats a rare autoimmune disorder that causes muscle weakness. these are all orphan drugs, which means biomarin can charge a great deal for them, because they save lives and save the system money, and the insurers welcome these. together these drugs are racking up over $500 million in sales. they have a lot m

so many of these little bioteches that have just absolutely nsp pharma, they've just rolled on over everybody let's take a look at an under the radar stock of the day. it is marketo. >> what is a town in minnesota. either way. san mateo software company a couple reassurances, outperform at wells fargo. under the radar name. they do marketing. >> coming up, jetblue rolling out bigger seats and better food and its ceo is here with more about the company's new mint section. stay tuned. >> it's cool. they always have. they always will. that's why you take charge of your future. your retirement. ♪ ameriprise advisors can help you like they've helped millions of others. listening, planning, working one on one. to help you retire your way... with confidence. that's what ameriprise financial does. that's what they can do with you. ameriprise financial. more within reach. i have a big meeting when we land, but i am so stuffed up, i can't rest. [ male announcer ] nyquil cold and flu liquid gels don't unstuff your nose. they don't? alka seltzer plus night fights your worst cold symptoms, plus has a deco

begin the conversation let me begin with a very flattering review of the book by professor thomas pharma of georgetown, renown leader in the world of religious freedom, and tribute to your notebook says this. one of the foremost religious liberty thinkers of our time, os guinness sets forth a soaring gold for this book, establishing a vision of religious freedom, civil freedom that accommodates competing truth claims about who man is and why he exists. os, help us understand what you mean by hassle freedom. >> guest: the term is from roger williams, sold liberty was his great thing. for me it is the right to reach, to hold, exercise, to change, and to share what you believe based on the dictates of conscience. that is easy to say that you can see all sorts of faults views. for example there were several american leaders a while back to talk about freedom of worship and that is quite inadequate. every dictator allows freedom of worship, what goes on in your head when your mouth shut between your two years. that is not free exercise as madison put out. or you can see in much of our world t

alone millions of americans are developing new sleep disorders and with them a new dependency on big pharma a full breakdown on how these sleep friendly drugs are ruling the nations later in the show.

american scholars 2011 the title is lacking for big pharma. very objective title. >> thank you very much. more and then you expected. >> thank you very much. my question is in relation to informed consent. .. >> the patents -- >> oh. >> yes. >> um, i think the last question first is easier. patents should not be banned, but they should be much more strictly controlled. and, in fact, that's what most other countries do. they permit patents, but they do not permit as many patents as we do. they don't permit a 20-year patent life which a company can easily extend by various, you know, manipulations. we have too many patted edges covering too many things -- patents covering too many things, and we allow them to persist for too long. they need to be tightly reined-anyone and controlled. a company holds a patent on a medication but they are making the medication at too high a price, $20,000 a year, or if they are not making the medication but holding the patent so nobody else can make it, then there is a regulation that says the government can step

foundation medicine, a cancer diagnostic company, only evoke pharma is at the low end. stanley estimating $22 billion in stock has to be sold in pension funds to rebalance. they do this at the end of every month and every quarter so we'll see a little gyration in stocks very soon. back to you zip want to see what the opens are like on two of those ipos. i want to come back to the story earlier in the week, that being blackberry. that was an interesting story. we covered it at the time. it was not during our show but jim and i both on the air at the time. fairfax making that offer, letter of intent i should say, $9 a share. when you look at the math and having spoken to a number of bankers, those who were involved in perhaps trying to sell the company and those who simply know their way around, as i tend to do after covering m&a for so many years now, ilt going to be a tough deal to pull off. the key there is the financing. let's assume it is a $5 billion deal. they do own 10%, that being fairfax. you'd want it to be overcapitalized. you're talking about raising $3 billi

>> johnson & johnson, a company called purdue pharma, indoe pharmaceutical.ard, everyone has their own version of an opioid. there's been a tremendous push to kred increase their use, spreads out their use. they were originally intended for cancer patients and people with very, very severe pain. >> you mentioned the really serious side effects. i think after an appendix, i think i took them for like three or four days and what happened after that was probably worse than -- and i'm talking about constipation. and it was probably worse than the -- any of the effects of the operation itself. it was beyond belief. >> yes. >> my life passed before my eyes. >> there are consequences to taking these drugs, but these drugs are necessary for, you know, after surgeries -- >> you have to stop after three or four days. you just have to stop after three or four days. >> you know, doctors need to prescribe these drugs to the people who need them. and when they prescribe them, they need to do them in very limited, controlled ways. i had a friend, his kid got this drug for 9

i like the pharmas. imagine the pharmaceuticals could be back here. they've done nothing for three months. the place to be. >> the smires? >> that thing goes to 43 today, you better get on board, you and your right wing pr prognostications. >> rick gets angry, i love that. >> general mills? >> you mentioned general mills yesterday. it was on the three to four. and you said the stock has done nothing. and i washoly cow, i know the margin was not that good for general mills, general mills and kellogg, that group has done nothing. it reignites today. >> because of the jobs number. >> yeah. 3% yield. people, look, people take these things -- they just run with it. not only do interest rates unless the central banks start coming in banging them down. they're going to talk about 2.75 and 2.6 and mortgage goes to 3.3 and go buy another house, two houses. >> i'm not going to follow in your footsteps. what are we, up to eight, nine. >> you're like mccain, can't even remember. >> house wrog project. >> he doesn't no we the restaurants, bars sdl that's coming. t